Transcutaneous Electric Nerve Stimulation (TENS) for Vagal Modulation

Sponsor
Virginia Commonwealth University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05987813
Collaborator
(none)
100
2
21.9

Study Details

Study Description

Brief Summary

This study is to determine if the auricular microstimulator produces the expected increase in HRV.

Condition or Disease Intervention/Treatment Phase
  • Device: TENS Unit
N/A

Detailed Description

The aim of this proposal is to determine if utilizing an affordable tool like microstimulation utilizing a transcutaneous electric nerve stimulator (TENS) unit and applying the stimulation to the ear though an ear clip does improve vagal modulation. This can be easily done at home by utilizing the microstimulation for 2 or 4 hours/day and measuring vagal modulation before and after. Previous research investigating this had participants use the unit for 2 hours. (Chelimsky et al., 2019). The data from this study was inconclusive, and by adding the 4 hour condition, this project can investigate if the inconclusive data was due to poor compliance or the need for a longer duration of use to improve vagal modulation.

Although functional gastrointestinal disorders (FGID) affect 10%-20% of children and adolescents. 1-3 the pathophysiology remains unknown. The multiple current hypotheses include visceral hypersensitivity, altered brain-gut connections, dysbiosis, genetic and epigenetic factors, and increased gut permeability among others. 4 Since the vagus nerve links the brain to the gut, many studies of adult subjects have evaluated the cardiovagal modulation in this group of disorders. The cardiovagal modulation can be measured by heart rate variability (HRV). HRV evaluates the heart rate fluctuation over a period of time. HRV is considered a reliable tool to look at parasympathetic function, baroreflex function, and parasympathetic to sympathetic balance.5, 6 High-frequency (hf) HRV is a marker of vagal modulation. The low-frequency (lf) HRV probably reflects cardiac autonomic outflow from the baroreflex or parasympathetic regulation, rather than sympathetic modulation, although this is still being discussed.6, 7

A meta-analysis of adult subjects with irritable bowel syndrome (IBS) showed decreased cardiovagal modulation.8 One study compared children aged 7-10 years of age with functional abdominal pain or IBS to healthy subjects. They found no difference in cardiovagal and cardiac sympathetic modulation.9 However, a study of young adolescents with different chronic pain syndromes, including chronic abdominal pain, showed decreased cardiovagal modulation.10 These findings are similar to those in many adult syndromes with chronic pain, such as chronic pelvic pain,11 complex regional pain syndrome,12 fibromyalgia,13 and chronic neck pain.14

Although future research would aim to investigate vagal modulation in those specifically with FGID, for preliminary data purposes we are testing the unit's effects on heart rate variability regardless of having/not having an FGID diagnosis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
FGID group, non-FGID group. Randomized to 2 or 4 hours of daily TENS usageFGID group, non-FGID group. Randomized to 2 or 4 hours of daily TENS usage
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Pilot Study of Randomized Auricular Microstimulation to Determine if it Improves Vagal Modulation
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: FGID

Patients with a FGID

Device: TENS Unit
Usage of the Transcutaneous Electrical Nerve Stimulation device for either 2 or 4 hours a day depending on randomization.

Experimental: Non-FGID

Patients without a FGID

Device: TENS Unit
Usage of the Transcutaneous Electrical Nerve Stimulation device for either 2 or 4 hours a day depending on randomization.

Outcome Measures

Primary Outcome Measures

  1. Change in high-frequency heart rate variability (hfHRV) at 4 weeks [Assessed at baseline and 4 weeks.]

    Determine if microstimulation to the conchae of the ear over a 4 week period results in improvement in hfHRV.

  2. Change in high-frequency heart rate variability (hfHRV) after 4 weeks of TENS use Determine if 4 hours/day of microstimulation increases hfHRV more significantly than 2 hours/day over a 4-week period [Assessed at baseline and 4 weeks.]

    Determine if 4 hours/day of microstimulation increases hfHRV more significantly than 2 hours/day over a 4-week period

  3. Rate of feasibility with daily TENS usage [Assessed daily for duration of study (4 weeks) via self-report recording journal.]

    Determine the feasibility of utilizing a microstimulator in adolescents.

  4. Rate of compliance with daily TENS usage [Assessed daily for duration of study (4 weeks) via self-report recording journal.]

    Determine the compliance rate of adolescents utilizing a microstimulator.

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 18 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Female

  • 12 - 18 years old

  • Either diagnosed OR not diagnosed with chronic idiopathic nausea, functional abdominal pain, dyspepsia and/or irritable bowel syndrome.

  • English speaking

Exclusion Criteria:
  • Patients who are unable to stand upright during the heart rate variability recording

  • Patients with a known bleeding disorder

  • Patients with swollen, infected, inflamed, or other skin eruptions on outer ear

  • Patients with epilepsy

  • Patients with any implanted cardiac pacemaker or defibrillator

  • Patients with serious arterial circulatory problems in the lower limbs

  • Patients with abdominal or inguinal hernia

  • Patients who are pregnant

  • Any unstable medical condition, such as renal disease, uncontrolled diabetes, etc.

  • Requires new medication during the 4 weeks of the study that may affect the gastrointestinal symptoms, vagal modulation or immune response.

  • Practices over 1 hour of aerobic activity a day

  • Daily practice of abdominal breathing (yoga)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Virginia Commonwealth University

Investigators

  • Principal Investigator: Gisela Chelimsky, MD, VCU

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT05987813
Other Study ID Numbers:
  • HM20025635
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 14, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 14, 2023